For Research Use Only Danirixin



www.ptgcn.com

Catalog Number: CM03605

产品信息

Catalog Number: CM03605 CAS号: 954126-98-8 分子式: C₁₉H₂₁ClFN₃O₄S

主要靶点: CXCR

主要通路: G蛋白偶联受体|自噬|免疫与炎症 分子量: 441.9 溶解度:

DMSO:8 mg/mL (18.10 mM),Sonification/heating is recommended.

OH III CH3

靶点活性

CXCL8-CXCR2:12.5 nM (cell free)

体内活性

Systemic exposure following single doses of danirixin 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg increased with increasing dose. Engagement of pharmacology was demonstrated as inhibition of ex-vivo CXCL1-induced CD11b expression on peripheral blood neutrophils when compared to placebo (approximately 50 % for 50 mg and 100 mg danirixin, and 72 % at 200 mg). There was a 37 % decrease in Cmax and a 16 % decrease in AUC (0-∞) following administration of danirixin in the presence of food. Cmax also decreased by 65 % when danirixin 100 mg was administered following omeprazole 40 mg once daily for 5 days [1].

描述

 $Danirix in is a potent \, antagonist \, of \, CXCR2 \, that \, inhibits \, IL-8 \, binding \, to \, CXCR2 \, (IC50: \, 12.5 \, nM).$

储存

Powder: -20°C for 3 years | In solvent: -80°C for 2 years